Expression level of the angiotensin 2 (ACE2) gene in patients with COVID-19

Basit Öğe Kaydı
dc.authoridAydin, Ismail Erkan/0000-0003-3552-5459
dc.contributor.authorDirican, Ebubekir
dc.contributor.authorAydin, Ismail Erkan
dc.contributor.authorSavrun, Seyda
dc.date.accessioned2024-10-04T18:51:00Z
dc.date.available2024-10-04T18:51:00Z
dc.date.issued2021
dc.departmentBayburt Üniversitesien_US
dc.description.abstractPurpose: Coronavirus disease-19 (COVID-19) is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2). The angiotensin converting enzyme 2 (ACE2) can play a vital role in regulating the pathological changes of various diseases, including COVID-19. The aim of this study was to analyze the expression of the ACE2 gene in Turkish COVID-19 patients. Materials and Methods: Eighty COVID-19 PCR test positive patients and 80 PCR test negative healthy volunteers were included in the study. RNA isolation was carried out from all samples. The RT-PCR device was used to analyze the expression of the ACE2 gene. Results: A significant difference was found in the age, Lactate dehydrogenase (LDH), ferritin and C-reactive protein (CRP) levels of the COVID-19 patients compared to the healthy volunteers. Based on the gene expression results, it was found that ACE2 gene expression was significantly higher in COVID-19 patients compared to healthy volunteers. In patients with COVID-19, a significant difference was found between the expression of the ACE2 gene and the levels of Blood urea nitrogen (BUN), Hemoglobin (HGB), Hematocrit (HCT) and CRP. Conclusion: ACE2 gene expression was high in the COVID-19 patients and showed differences based on clinical data. Thus, the expression of ACE2 can have paradoxical effects that support the pathogenicity of SARSCoV2 but, conversely, limit viral infection. The availability of ACE2 receptors may increase the susceptibility and / or disease course of COVID-19.en_US
dc.identifier.doi10.17826/cumj.982658
dc.identifier.endpage1515en_US
dc.identifier.issn2602-3032
dc.identifier.issn2602-3040
dc.identifier.issue4en_US
dc.identifier.startpage1508en_US
dc.identifier.trdizinid468333en_US
dc.identifier.urihttps://doi.org/10.17826/cumj.982658
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/468333
dc.identifier.urihttp://hdl.handle.net/20.500.12403/3315
dc.identifier.volume46en_US
dc.identifier.wosWOS:000728748600024en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isotren_US
dc.publisherCukurova Univ, Fac Medicineen_US
dc.relation.ispartofCukurova Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectACE-2en_US
dc.subjectLactate dehydrogenaseen_US
dc.subjectCRPen_US
dc.subjectBUNen_US
dc.subjectHemoglobinen_US
dc.titleExpression level of the angiotensin 2 (ACE2) gene in patients with COVID-19en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu